STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCUS
  4. [Form 4] Arcus Biosciences, Inc. Insider Trading Activity

Arcus Biosciences (RCUS) CEO receives 79,000 RSUs, 315,000 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcus Biosciences Chief Executive Officer Terry J. Rosen reported new equity awards. On January 23, 2026, he received 79,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues to serve the company.

On the same date, he was also granted stock options for 315,000 shares of Arcus common stock with an exercise price of $22.13 per share. The options become exercisable in 48 equal monthly installments after January 1, 2026, contingent on his continued service. After these transactions, Rosen beneficially owned 2,236,409 shares of common stock directly, including unvested RSUs.

Positive

  • None.

Negative

  • None.
Insider ROSEN TERRY J
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 315,000 $0.00 --
Grant/Award Common Stock 79,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 315,000 shares (Direct); Common Stock — 2,236,409 shares (Direct)
Footnotes (1)
  1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROSEN TERRY J
(Last) (First) (Middle)
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
(Street)
HAYWARD CA 94545
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2026 A 79,000(1) A $0 2,236,409(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $22.13 01/23/2026 A 315,000 (3) 01/22/2036 Common Stock 315,000 $0 315,000 D
Explanation of Responses:
1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
2. Includes the unvested portion of the Reporting Person's RSU grants.
3. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Remarks:
/s/ Carolyn Tang, Attorney-in-Fact 01/26/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for its CEO?

Arcus Biosciences reported that its Chief Executive Officer, Terry J. Rosen, received two equity grants on January 23, 2026: 79,000 restricted stock units of common stock and stock options for 315,000 shares.

How many Arcus Biosciences (RCUS) RSUs were granted to the CEO and how do they vest?

The CEO received 79,000 restricted stock units of Arcus common stock. These RSUs vest in four equal annual installments starting on December 15, 2026, subject to his continued service to the company.

What are the terms of the 315,000 Arcus Biosciences (RCUS) stock options granted to the CEO?

The stock option grant covers 315,000 shares of Arcus common stock with an exercise price of $22.13 per share. The options become exercisable in 48 equal monthly installments after January 1, 2026, contingent on Terry J. Rosen’s continued service.

What is the CEO’s total reported Arcus Biosciences (RCUS) common stock ownership after these grants?

Following the reported transactions, Terry J. Rosen beneficially owned 2,236,409 shares of Arcus Biosciences common stock directly. This total includes the unvested portion of his restricted stock unit grants.

Were the newly reported Arcus Biosciences (RCUS) insider transactions purchases or awards?

The transactions were equity awards to the CEO, not market purchases or sales. They consist of a grant of restricted stock units and a grant of stock options, both reported with a grant price of $0 for the awards themselves.

What roles does Terry J. Rosen hold at Arcus Biosciences (RCUS)?

Terry J. Rosen is reported as both a Director and the Chief Executive Officer of Arcus Biosciences, Inc., according to the insider filing.